2023-02-27 ペンシルベニア州立大学(PennState)
この研究により、非侵襲的なリキッドバイオプシーがGBMの患者の治療や進行状況の追跡に役立ち、より迅速なケアを提供できる可能性があります。この研究では、IL13Rα2と呼ばれる特定の抗原受容体が、GBM患者の腫瘍組織に著しく過剰に発現していることが判明しました。また、血漿中のIL13Rα2レベルが高い患者は、低い患者に比べて全体的な生存期間が6.5ヶ月長いことが示されました。
<関連情報>
- https://www.psu.edu/news/research/story/blood-test-brain-cancer-may-be-horizon-new-research-finds/
- https://link.springer.com/article/10.1007/s11060-022-04196-0
膠芽腫の新規リキッドバイオプシーバイオマーカーとしての血漿中IL13Rα2 Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma
Vladimir Khristov,Darya Nesterova,Mara Trifoi,Taylor Clegg,Annika Daya,Thomas Barrett,Emily Tufano,Ganesh Shenoy,Bhavyata Pandya,Gela Beselia,Nataliya Smith,Oliver Mrowczynski,Brad Zacharia,Kristin Waite,Justin Lathia,Jill Barnholtz-Sloan & James Connor
Journal of Neuro-Oncology Published:27 November 2022
DOI:https://doi.org/10.1007/s11060-022-04196-0
Abstract
Purpose
Glioblastoma (GBM) is the most common and deadliest brain tumor with unrelenting and rapid disease progression. The standard of care for GBM is surgical excision followed by radiation with concurrent and adjuvant temozolomide-centered chemotherapy (TMZ). Treatment failure and resistance is the rule and despite advances in imaging technology, early detection of treatment failure or impending resistance remains a challenge. There is a dire, unmet, need in clinical practice for minimally-invasive diagnostic tools to enable timely understanding of disease progression and treatment response. Here, we aim to address this clinical need by leveraging a unique characteristic of GBM: the overexpression of the α2 variant of the IL-13 receptor in over 75% of GBM tumors.
Methods
In this study we examined patients with primary GBM from Penn State and Cleveland Clinic compared to healthy controls.
Results
IL13Rα2 was detectable in plasma of GBM patients using ELISA but detection could be optimized by PEG precipitation to enrich for extracellular vesicles (EVs). Patients with GBM had elevated levels of plasma IL13Rα2, which correlated to levels of this receptor in the tumor tissue. Elevated plasma levels of IL13Rα2 predicted longer overall survival (OS) (19.8 vs. 13.2 months). Similarly, detection of IL13Rα2 + cells in tumor tissue also predicted longer OS (22.1 vs. 12.2 months).
Conclusion
These findings strongly suggest that expression of the IL13Rα2 receptor confer survival advantage in GBM patients, which can be determined through a minimally-invasive liquid biopsy. Detection of plasma IL13Rα2 can also be used to select GBM patients for targeted tumor therapy.
